LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
Sonrotoclax + Zanubrutinib Well Tolerated Deep Responses TN-CLL/SLL [ASH 2023]
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center,…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study…
Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 Practice patterns for sequential use of antibody-drug conjugate after antibody-drug 1
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist…
OLAnzaPiNE-3: Low-Dose vs Standard-Dose Olanzapine in Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy in Solid Tumor
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a…
BTK Degrader BGB-16673:Phase 1 Results in B-Cell Malignancies [ASH 2023]
John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…